Virologic suppression can be maintained among patients with HIV infection receiving integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART) in combination with short-course rifapentine-based regimens for latent tuberculosis (TB) management, according to study results published in Clinical Infectious Diseases.

Exposure to isoniazid prevention therapy during the first trimester of pregnancy is associated with increased risk for fetal demise, according to study results published in Clinical Infectious Diseases.

There was a low risk for post-treatment recurrence among patients who received treatment for multidrug- or rifampicin-resistant tuberculosis infection.

There was a significant gap in TB diagnostic care both before and during the COVID-19 pandemic among hospitalized patients with advanced HIV infection.

Weight-based dosing of bedaquiline for multidrug/rifampicin-resistant (MDR/RR) tuberculosis (TB) infection was safe and effective among children with and without HIV coinfection, according to findings published in Clinical Infectious Diseases.

Results of a study called into question the recommendation for meropenem with amoxicillin and clavulanate to be used as a second-line therapy for drug-resistant tuberculosis (TB). These findings were published in the American Journal of Respiratory and Critical Care Medicine.

Results of a phase 3 randomized trial found that daily treatment with high-dose rifapentine for tuberculosis (TB) infection decreased efavirenz clearance and achieved therapeutic targets among patients coinfected with HIV receiving efavirenz-based antiretroviral therapy (ART). These findings were published in Clinical Infectious Diseases.

The far less-invasive collection and testing of nasopharyngeal aspirate (NPA) samples in combination with stool and urine sample testing may improve the diagnosis of tuberculosis (TB) in children in limited-resource settings. This finding from a prospective, cross-sectional diagnostic study, was published in JAMA Pediatrics.

Patients with multidrug-resistant or rifampicin-resistant tuberculosis (TB) and a normal baseline QTc interval may benefit from bedaquiline plus delamanid combination therapy, according to the findings of a study published in The Lancet Infectious Diseases.

Risk for active tuberculosis (TB) may be reduced with the use of statins. This finding was published in a letter to the editor in the Journal of Infectious Diseases.¹